| Company Name: | Genentech Inc | | Ticker Symbol: | DNA | | | WWW Address: | www.gene.com | | CEO: | Dr. Arthur D. Levinson, Ph.D. | | No. of Employees: | 11,186 | | Common Issue Type: | CS | | Business Description: | A biotechnology company that discovers, develops, manufactures and commercializes medicines for patients with significant unmet medical needs.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 94.97 |  0.0 | - | - | 0 | 95.00 | 94.97 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 99,908.4 | 1,052.0 | 0.12 | 3.21 | 0.00 | 29.6 | 0.0 | 99.14 - 66.80 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 94.97 | $ | | PE Ratio - LTM | 29.6 | |
| Market Capitalisation | 99,911.6 | mil |
| Latest Shares Outstanding | 1,052.0 | mil |
| Earnings pS (EPS) | 3.21 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 1,199,535 | $ |
| Effective Tax Rate | 36.9 | % |
| Float | 1,052.0 | mil |
| Float as % of Shares Outstanding | 100.0 | % |
| Foreign Sales | 1,028 | mil |
| Domestic Sales | 9,503 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 26.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 20.90 | % |
| Gross Profit Margin | 91.4 | % |
| EBITDA Margin | 44.1 | % |
| Pre-Tax Profit Margin | 40.5 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 15.7 | % |
| Return on Equity (ROE) | 21.9 | % |
| Return on Capital Invested (ROCI) | 19.0 | % |
| Current Ratio | 3.3 | |
| Leverage Ratio (Assets/Equity) | 1.4 | |
| Interest Cover | 67.2 | |
| Total Debt/Equity (Gearing Ratio) | 0.18 | |
| LT Debt/Total Capital | 13.0 | % |
| Working Capital pS | 6.63 | $ |
| Cash pS | 4.31 | $ |
| Book-Value pS | 14.90 | $ |
| Tangible Book-Value pS | 12.43 | $ |
| Cash Flow pS | 3.82 | $ |
| Free Cash Flow pS | 3.05 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 6.37 | |
| Price/Tangible Book Ratio | 7.64 | |
| Price/Cash Flow | 24.9 | |
| Price/Free Cash Flow | 31.1 | |
| P/E as % of Industry Group | 175.0 | % |
| P/E as % of Sector Segment | 34.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.3 | 95 | 137,254 | 410,888 |
| 4 Weeks | 95.00 | 81.26 | 85.55 | 11.0 | 100 | 174,640 | 3,492,799 |
| 13 Weeks | 95.00 | 80.57 | 82.21 | 15.5 | 124 | 84,306 | 5,226,996 |
| 26 Weeks | 95.00 | 69.17 | 91.19 | 4.1 | 155 | 66,714 | 8,339,262 |
| 52 Weeks | 99.14 | 66.80 | 80.00 | 18.7 | 191 | 55,824 | 14,067,614 |
| YTD | 95.00 | 80.57 | - | 14.5 | 127 | 87,689 | 5,173,658 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 94.69 | 94.26 | 86.78 | 84.57 | 85.31 | 0.12 | 0.04 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 38.54 | 96.4 | 26.44 |
| Income | 44.61 | 98.1 | 38.77 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 22.94 | NA | -13.47 |
| R&D | 32.92 | NA | 31.15 |
| Normalized Inc. | 40.83 | NA | 32.52 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 14.4 | 24.9 | 14.4 |
| Earnings % | 23.8 | 47.7 | 23.8 |
| EPS % | 23.9 | 47.5 | 23.9 |
| EPS $ | 0.62 | 0.28 | 0.62 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 32.03 |
| Current Ratio | 3.3 |
| Quick Ratio (Acid Test) | 2.6 |
| Liquidity Ratio (Cash) | 2.00 |
| Receivables Turnover | 7.2 |
| Average Collection Period | 50 |
| Working Capital/Equity | 44.5 |
| Working Capital pS | 6.62 |
| Cash-Flow pS | 3.82 |
| Free Cash-Flow pS | 3.04 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 11.84 |
| Financial Leverage Ratio (Assets/Equity) | 1.4 |
| Debt Ratio | 28.1 |
| Total Debt/Equity (Gearing Ratio) | 0.18 |
| LT Debt/Equity | 0.15 |
| LT Debt/Capital Invested | 16.8 |
| LT Debt/Total Liabilities | 38.1 |
| Interest Cover | 67.2 |
| Interest/Capital Invested | 0.44 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 7.07 |
| Tobin's Q Ratio | 4.59 |
| Current P/E Ratio - LTM | 29.60 |
| Enterprise Value (EV)/EBITDA | 16.86 |
| Enterprise Value (EV)/Free Cash Flow | 33.44 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 7.64 |
| Price/Book Ratio - LTM | 6.37 |
| Price/Cash Flow Ratio | 24.9 |
| Price/Free Cash Flow Ratio - LTM | 31.1 |
| Price/Sales Ratio | 7.45 |
| P/E Ratio (1 month ago) - LTM | 26.7 |
| P/E Ratio (26 weeks ago) - LTM | 31.7 |
| P/E Ratio (52 weeks ago) - LTM | 30.9 |
| 5-Y High P/E Ratio | 93.5 |
| 5-Y Low P/E Ratio | 20.4 |
| 5-Y Average P/E Ratio | 49.2 |
| Current P/E Ratio as % of 5-Y Average P/E | 60 |
| P/E as % of Industry Group | 175.0 |
| P/E as % of Sector Segment | 34.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 29.6 |
| PER SHARE FIGURES |
| LT Debt pS | 2.21 |
| Current Liabilities pS | 2.94 |
| Tangible Book Value pS - LTM | 12.43 |
| Book Value pS - LTM | 14.90 |
| Capital Invested pS | 17.11 |
| Cash pS - LTM | 4.31 |
| Cash Flow pS - LTM | 3.82 |
| Free Cash Flow pS - LTM | 3.05 |
| Earnings pS (EPS) | 3.21 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 23.88 |
| Free Cash Flow Margin 5YEAR AVG | 14.39 |
| Net Profit Margin | 25.5 |
| Net Profit Margin - 5YEAR AVRG. | 23.0 |
| Equity Productivity | 0.86 |
| Return on Equity (ROE) | 21.9 |
| Return on Equity (ROE) - 5YEAR AVRG. | 20.2 |
| Capital Invested Productivity | 0.75 |
| Return on Capital Invested (ROCI) | 19.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 17.1 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | 15.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | 13.5 |
| Gross Profit Margin | 91.4 |
| Gross Profit Margin - 5YEAR AVRG. | 91.2 |
| EBITDA Margin - LTM | 44.1 |
| EBIT Margin - LTM | 41.1 |
| Pre-Tax Profit Margin | 40.5 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 36.6 |
| Effective Tax Rate | 36.9 |
| Effective Tax Rate - 5YEAR AVRG. | 36.9 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 488 |
| Revenue per Employee | 1,199,535 |
| Net Income per Employee | 306,365 |
| Average Collection Period | 52 |
| Receivables Turnover | 7.2 |
| Day's Inventory Turnover Ratio | 436 |
| Inventory Turnover | 0.8 |
| Inventory/Sales | 9.7 |
| Accounts Payble/Sales | 1.70 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 1.92 |
| Fixed Assets Turnover | 1.15 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 2.96 |
| Revenue per $ Plant | 2.48 |
| Revenue per $ Common Equity | 0.86 |
| Revenue per $ Capital Invested | 0.75 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 26.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 28.5 |
| Research & Devlopment (R&D) as % of Revenue | 20.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 20.9 |
|
|  
| | |  |  | |
| |